Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 19/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23862416 | 1.00 | FOLH1 (0.64) | FOLH1ALB | |
| SCHEMBL31391930 | 1.00 | FOLH1 (0.64) | FOLH1ALB | |
| SCHEMBL23862408 | 1.00 | FOLH1 (0.64) | FOLH1ALB | |
| SCHEMBL23252352 | 1.00 | FOLH1 (0.64) | FOLH1ALB | |
| SCHEMBL26382169 | 1.00 | FOLH1 (0.64) | FOLH1ALB | |
| SCHEMBL21901407 | 0.98 | FOLH1 (0.61) | FOLH1ALB | |
| SCHEMBL20283295 | 0.97 | FOLH1 (0.66) | FOLH1ALB | |
| SCHEMBL25138620 | 0.96 | ALB (0.62) | FOLH1ALB | |
| SCHEMBL20180903 | 0.96 | ALB (0.62) | FOLH1ALB | |
| SCHEMBL23862423 | 0.96 | ALB (0.62) | FOLH1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239829-A2 | SYSTEMS AND METHODS FOR ASSESSING DISEASE BURDEN AND PROGRESSION | PROGENICS PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-11657508-B2 | Systems and methods for platform agnostic whole body image segmentation | EXINI DIAGNOSTICS AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-20230122957-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2023-04-20 | — | — | US | disclosed |
| US-10980901-B2 | Treatment of PMSA expressing cancers | THE EUROPEAN ATOMIC ENERGY COMMUNITY (EURATOM), REPRESENTED BY THE EUROPEAN COMMISSION (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20200357521-A1 | NETWORK FOR MEDICAL IMAGE ANALYSIS, DECISION SUPPORT SYSTEM, AND RELATED GRAPHICAL USER INTERFACE (GUI) APPLICATIONS | CITIZENS BANK, N.A. | 2020-11-12 | — | — | US | disclosed |
| US-20200297876-A1 | PSMA ligands for imaging and endoradiotherapy | Technische Universität München (DE) | 2020-09-24 | — | — | US | disclosed |
| US-10762993-B2 | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications | PROGENICS PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10665346-B2 | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications | PROGENICS PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122957-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | KLK3, FOLH1, EEA1 | FOLH1 2/4885ALB 1225/4885 |
| US-20230173112-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | FOLH1 3/4885ALB 948/4885 |
| US-11657508-B2 | Systems and methods for platform agnostic whole body image segmentation | HTR3D, SSTR3, ERBB3 | FOLH1 709/4885ALB 336/4885 |
| US-20200297876-A1 | PSMA ligands for imaging and endoradiotherapy | KLK3, FOLH1, EEA1 | FOLH1 2/4885ALB 1225/4885 |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | KLK3, SHBG, SELPLG | FOLH1 8/4885ALB 1141/4885 |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | FOLH1 3/4885ALB 1065/4885 |
| US-10980901-B2 | Treatment of PMSA expressing cancers | PMS2, GNRHR, MC5R | FOLH1 4/4885ALB 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.